Amyloid β1-42 oligomer inhibits myelin sheet formation in vitro

Neurobiology of Aging

Volumn 33, Issue 3, 2012, Pages 499-509

  Horiuchi, Makoto ^a,b   Maezawa, Izumi ^c   Itoh, Aki ^a,b   Wakayama, Kouji ^a,b   Jin, Lee Way ^c   Itoh, Takayuki ^a,b   DeCarli, Charles ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SHRINERS HOSPITALS FOR CHILDREN NORTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Amyloid ; Lipid; Myelin; Oligodendroglia; White matter degeneration

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMYLOID BETA PROTEIN[1-42]; FORMAZAN; OLIGOMER;

ANIMAL CELL; ARTICLE; AXONAL INJURY; BRAIN DEGENERATION; CELL DIFFERENTIATION; CELL LINEAGE; CELL MATURATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DEVELOPMENTAL STAGE; EXOCYTOSIS; IN VITRO STUDY; INHIBITION KINETICS; MITOSIS INHIBITION; MYELIN SHEATH; NERVE CELL NETWORK; NONHUMAN; OLIGODENDROGLIA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REMYELINIZATION; STEM CELL; WHITE MATTER;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANIMALS, NEWBORN; MYELIN SHEATH; NERVE FIBERS, MYELINATED; OLIGODENDROGLIA; PEPTIDE FRAGMENTS; PRIMARY CELL CULTURE; RATS; RATS, INBRED LEW; STEM CELLS; TUMOR CELLS, CULTURED; WALLERIAN DEGENERATION;

EID: 84855759780     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.05.007     Document Type: Article

References (55)

1. Abe K., Saito H. Amyloid β protein inhibits cellular MTT reduction not by suppression of mitochondrial succinate dehydrogenase but by acceleration of MTT formazan exocytosis in cultured rat cortical astrocytes. Neurosci. Res. 1998, 31:295-305.
2. Barber R., Scheltens P., Gholkar A., Ballard C., McKeith I., Ince P., Perry R., O'Brien J. White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer's disease, vascular dementia, and normal aging. J. Neurol. Neurosurg. Psychiatry 1999, 67:66-72.
3. Bartzokis G. Age-related myelin breakdown: a developmental model of cognitive decline and Alzheimer's disease. Neurobiol. Aging 2004, 25:5-18.
4. Baumann N., Pham-Dinh D. Biology of oligodendrocyte and myelin in the mammalian central nervous system. Physiol. Rev. 2001, 81:871-927.
5. Chen S., Lee J.-M., Zeng C., Chen H., Hsu C.Y., Xu J. Amyloid beta peptide increases DP5 expression via activation of neutral sphingomyelinase and JNK in oligodendrocytes. J. Neurochem. 2006, 97:631-640.
6. Cho H., Yang D.W., Shon Y.M., Kim B.S., Kim Y.I., Choi Y.B., Lee K.S., Shim Y.S., Yoon B., Kim W., Ahn K.J. Abnormal integrity of corticocortical tracts in mild cognitive impairment: a diffusion tensor imaging study. J. Korean Med. Sci. 2008, 23:477-483.
7. Chua T.C., Wen W., Slavin M.J., Sachdev P.S. Diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease: a review. Curr. Opin. Neurol. 2008, 21:83-92.
8. de Vries H., Schrage C., Hoekstra D. An apical-type trafficking pathway is present in cultured oligodendrocytes but the sphingolipid-enriched myelin membrane is the target of a basolateral-type pathway. Mol. Biol. Cell 1998, 9:599-609.
9. Debruin L.S., Harauz G. White matter rafting -membrane microdomains in myelin. Neurochem. Res. 2007, 32:213-228.
10. Desai M.K., Sudol K.L., Janelsins M.C., Mastrangelo M.A., Frazer M.E., Bowers W.J. Triple-transgenic Alzheimer's disease mice exhibit region-specific abnormalities in brain myelination patterns prior to appearance of amyloid and tau pathology. Glia 2009, 57:54-65.
11. Diaz G., Melis M., Musin A., Piludu M., Piras M., Falchi A.M. Localization of MTT formazan in lipid droplets. An alternative hypothesis about the nature of formazan granules and aggregates. Eur. J. Histochem. 2007, 51:213-218.
12. Gielen E., Baron W., Vandeven M., Steels P., Hoekstra D., Ameloot M. Rafts in oligodendrocytes: evidence and structure-function relationship. Glia 2006, 54:499-512.
13. Gunning-Dixon F.M., Raz N. The cognitive correlates of white matter abnormalities in normal aging: a quantitative review. Neuropsychology 2000, 14:224-232.
14. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
15. Harms M.P., Kotyk J.J., Merchant K.M. Evaluation of white matter integrity in ex vivo brains of amyloid plaque-bearing APPsw transgenic mice using magnetic resonance diffusion tensor imaging. Exp. Neurol. 2006, 199:408-415.
16. Hong H.S., Maezawa I., Yao N., Xu B., Diaz-Avalos R., Rana S., Hua D.H., Cheng R.H., Lam K.S., Jin L.-W. Combining the rapid MTT formazan exocytosis assay and the MC65 protection assay led to the discovery of carbazole analogs as small molecule inhibitors of Aβ oligomer-induced cytotoxicity. Brain Res. 2007, 1130:223-234.
17. Horiuchi M., Itoh A., Pleasure D., Itoh T. MEK-ERK signaling is involved in interferon-γ-induced death of oligodendroglial progenitor cells. J. Biol. Chem. 2006, 281:20095-20106.
18. + oligodendroglial progenitor cells. J. Neurosci. Res. 2010, 88:957-970.
19. Itoh T., Beesley J., Itoh A., Cohen A.S., Kavanaugh B., Coulter D.A., Grinspan J.B., Pleasure D. AMPA glutamate receptor-mediated calcium signaling is transiently enhanced during development of oligodendrocytes. J. Neurochem. 2002, 81:390-402.
20. Itoh T., Itoh A., Pleasure D. Bcl-2-related protein family gene expression during oligodendroglial differentiation. J. Neurochem. 2003, 85:1500-1512.
21. Itoh T., Reddy U.R., Stern J.L., Chen M., Itoh A., Pleasure D. Diminished calcium homeostasis and increased susceptibility to excitotoxicity of JS. 3/sixteen progenitor cells after differentiation to oligodendroglia. Glia 2000, 31:165-180.
22. Jantaratnotai N., Ryu J.K., Kim S.U., McLarnon J.G. Amyloid β peptide-induced corpus callosum damage and glial activation in vivo. Neuroreport 2003, 14:1429-1433.
23. Kadish I., Thibault O., Blalock E.M., Chen K.-C., Gant J.C., Porter N.M., Landfield P.W. Hippocampal and cognitive aging across the lifespan: a bioenergetic shift precedes and increased cholesterol trafficking parallels memory impairment. J. Neurosci. 2009, 29:1805-1816.
24. Kavcic V., Ni H., Zhu T., Zhong J., Duffy C.J. White matter integrity linked to functional impairments in aging and early Alzheimer's disease. Alzheimers Dement. 2008, 4:381-389.
25. Klein W.L. Aβ toxicity in Alzheimer's disease: globular oligomers (ADDLs) as new vaccine and drug targets. Neurochem. Int. 2002, 41:345-352.
26. 1-42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:6448-6453.
27. Lee D.Y., Fletcher E., Martinez O., Ortega M., Zozulya N., Kim J., Tran J., Buonocore M., Carmichael O., deCarli C. Regional pattern of white matter microstructural changes in normal aging, MCI, and AD. Neurology 2009, 73:1722-1728.
28. Lee J.-T., Xu J., Lee J.-M., Ku G., Han X., Yang D.-I., Chen S., Hsu C.Y. Amyloid-β peptide induces oligodendrocyte death by activating the neutral sphingomyelinase-ceramide pathway. J. Cell Biol. 2004, 164:123-131.
29. Lintner R.N., Dyer C.A. Redistribution of cholesterol in oligodendrocyte membrane sheets after activation of distinct signal transduction pathways. J. Neurosci. Res. 2000, 15:437-449.
30. Liu Y., Dargusch R., Banh C., Miller C.A., Schubert D. Detecting bioactive amyloid β peptide species in Alzheimer's disease. J. Neurochem. 2004, 91:648-656.
31. Liu Y., Peterson D.A., Kimura H., Schubert D. Mechanism of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction. J. Neurochem. 1997, 69:581-593.
32. Liu Y., Peterson D.A., Schubert D. Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:13266-13271.
33. Liu Y., Piasecki D. A cell-based method for the detection of nanomolar concentrations of bioactive amyloid. Anal. Biochem. 2001, 289:130-136.
34. Ma Q.L., Yang F., Calon F., Ubeda O.J., Hansen J.E., Weisbart R.H., Beech W., Frautschy S.A., Cole G.M. p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis. J. Biol. Chem. 2008, 283:14132-14143.
35. Maezawa I., Hong H.S., Liu R., Wu C.Y., Cheng R.H., Kung M.P., Kung H.F., Lam K.S., Oddo S., Laferla F.M., Jin L.-W. Congo red and thioflavin-T analogs detect Abeta oligomers. J. Neurochem. 2008, 104:457-468.
36. Maezawa I., Hong H.S., Wu H.C., Battina S.K., Rana S., Iwamoto T., Radke G.A., Pettersson E., Martin G.M., Hua D.H., Jin L.W. Congo red and thioflavin-T analogs detect Abeta oligomers. J. Neurochem. 2006, 98:57-67.
37. Maier O., De Jonge J., Nomden A., Hoekstra D., Baron W. Lovastatin induces the formation of abnormal myelin-like membrane sheets in primary oligodendrocytes. Glia 2009, 57:402-413.
38. Maier O., Hoekstra D., Baron W. Polarity development in oligodendrocytes: sorting and trafficking of myelin components. J. Mol. Neurosci. 2008, 35:35-53.
39. Miron V.E., Zehntner S.P., Kuhlmann T., Ludwin S.K., Owens T., Kennedy T.E., Bedell B.J., Antel J.P. Statin therapy inhibits remyelination in the central nervous system. Am. J. Pathol. 2009, 174:1880-1890.
40. Nakata Y., Sato N., Nemoto K., Abe O., Shikakura S., Arima K., Furuta N., Uno M., Hirai S., Masutani Y., Ohtomo K., Barkovich A.J., Aoki S. Diffusion abnormality in the posterior cingulum and hippocampal volume: correlation with disease progression in Alzheimer's disease. Magn. Reson. Imaging 2009, 27:347-354.
41. Nishiyama A., Komitova M., Suzuki R., Zhu X. Polydendrocytes (NG2 cells): multifunctional cells with lineage plasticity. Nat. Rev. Neurosci. 2009, 10:9-22.
42. Peters A., Sethares C. Is there remyelination during aging of the primate central nervous system?. J. Comp. Neurol. 2003, 460:238-254.
43. Polito A., Reynolds R. NG2-expressing cells as oligodendrocyte progenitors in the normal and demyelinated adult central nervous system. J. Anat. 2005, 207:707-716.
44. Raff M.C., Miller R.H., Noble M. A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature 1983, 303:390-396.
45. Roher A.E., Weiss N., Kokjohn T.A., Kuo Y.-M., Kalback W., Anthony J., Watson D., Luehrs D.C., Sue L., Walker D., Emmerling M., Goux W., Beach T. Increased Aβ peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 2002, 41:11080-11090.
46. Song J., Goetz B.D., Baas P.W., Duncan I.D. Cytoskeletal reorganization during the formation of oligodendrocyte processes and branches. Mol. Cell. Neurosci. 2001, 17:624-636.
47. Stokin G.B., Lillo C., Falzone T.L., Brusch R.G., Rockenstein E., Mount S.L., Raman R., Davies P., Masliah E., Williams D.S., Goldstein L.S. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's disease. Science 2005, 307:1282-1288.
48. Sun S.W., Song S.K., Harms M.P., Lin S.J., Holtzman D.M., Merchant K.M., Kotyk J.J. Detection of age-dependent brain injury in a mouse model of brain amyloidosis associated with Alzheimer's disease using magnetic resonance diffusion tensor imaging. Exp. Neurol. 2005, 191:77-85.
49. Taguchi K., Yoshinaka K., Yoshino K., Yonezawa K., Maekawa S. Biochemical and morphologic evidence of the interaction of oligodendrocyte membrane rafts with actin filaments. J. Neurosci. Res. 2005, 81:218-225.
50. Thomas M.G., Santa Coloma T.A., Correale J., Boccaccio G.L. Myosin light chain kinase inhibitors induce retraction of mature oligodendrocyte processes. Neurochem. Res. 2002, 27:1305-1312.
51. Wirths O., Weis J., Kayed R., Saido T.C., Bayer T.A. Age-dependent axonal degeneration in an Alzheimer mouse model. Neurobiol. Aging 2007, 28:1689-1699.
52. Yoshita M., Fletcher E., Harvey D., Ortega M., Martinez O., Mungas D.M., Reed B.R., DeCarli C.S. Extent and distribution of white matter hyperintensities in normal aging, MCI, and AD. Neurology 2006, 67:2192-2198.
53. Zeng C., Lee J.T., Chen H., Chen S., Hsu C.Y., Xu J. Amyloid-β peptide enhances tumor necrosis factor-α-induced iNOS through neural sphingomyelinase/ceramide pathway in oligodendrocytes. J. Neurochem. 2005, 94:703-712.
54. Zhao L., Ma Q.-L., Calon F., Harris-White M.E., Yang F., Lim G.P., Morihara T., Ubeda O.J., Ambegaokar S., Hansen J.E., Weisbart R.H., Teter B., Frautschy S.A., Cole G.M. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. Nat. Neurosci. 2006, 9:234-242.
55. Zhou Y., Dougherty J.H., Hubner K.F., Bai B., Cannon R.L., Hutson R.K. Abnormal connectivity in the posterior cingulate and hippocampus in early Alzheimer's disease and mild cognitive impairment. Alzheimers Dement. 2008, 4:265-270.